文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

HPV自采样对筛查不足美国女性后续宫颈癌筛查完成率的影响:MyBodyMyTest-3随机对照试验方案

Impact of human papillomavirus (HPV) self-collection on subsequent cervical cancer screening completion among under-screened US women: MyBodyMyTest-3 protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-12-27

本研究为随机对照试验方案,计划纳入至少510名25-64岁、过去4年无Pap涂片且6年无HPV检测的美国低收入女性,随机分为邮寄HPV自采样套件组与对照组,两组均接受预约协助。主要结局为宫颈癌筛查完成率,即临床筛查完成或自采样HPV阴性;同时评估感知风险的中介作用及增量成本。

要点

  • 邮寄HPV自采样套件可能提高筛查不足女性的宫颈癌筛查完成率。
  • 主要结局定义为临床筛查完成或自采样HPV阴性结果。
  • 将评估自采样对感知风险的影响及增量成本。

核心结论

  • 若邮寄自采样有效,可能降低医疗服务不足女性的宫颈癌发病率和死亡率。

研究设计与样本

  • 随机对照试验,计划纳入至少510名25-64岁、过去4年无Pap涂片且6年无HPV检测的美国低收入女性。

关键数值与推荐

  • 主要结局为筛查完成:临床筛查或自采样HPV阴性视为完成;其他参与者若在研究机构或其他诊所接受联合检测或Pap涂片也视为完成。
  • 将评估自采样干预是否影响感知风险及感知风险是否中介自采样结果与后续临床筛查的关系。
  • 将估计与仅提供预约协助相比,提供居家HPV自采样套件加预约协助的每名女性筛查增量成本。

临床怎么用

  • 干预组接受居家自采样套件并邮寄进行HPV检测,两组均接受预约协助。
  • 研究 staff 通过电话告知HPV自采样结果并协助预约临床筛查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Screening substantially reduces cervical cancer incidence and mortality. More than half of invasive cervical cancers are attributable to infrequent screening or not screening at all. The current study, My Body My Test (MBMT), evaluates the impact of mailed kits for self-collection of samples for human papillomavirus (HPV) testing on completion of cervical cancer screening in low-income, North Carolina women overdue for cervical cancer screening. METHODS/DESIGN: The study will enroll at least 510 US women aged 25-64 years who report no Pap test in the last 4 years and no HPV test in the last 6 years. We will randomize participants to an intervention or control arm. The intervention arm will receive kits to self-collect a sample at home and mail it for HPV testing. In both the intervention and control arms, participants will receive assistance in scheduling an appointment for screening in clinic. Study staff will deliver HPV self-collection results by phone and assist in scheduling participants for screening in clinic. The primary outcome is completion of cervical cancer screening. Specifically, completion of screening will be defined as screening in clinic or receipt of negative HPV self-collection results. Women with HPV-negative self-collection results will be considered screening-complete. All other participants will be considered screening-complete if they obtain co-testing or Pap test screening at a study-affiliated institution or other clinic. We will assess whether the self-collection intervention influences participants' perceived risk of cervical cancer and whether perceived risk mediates the relationship between HPV self-collection results and subsequent screening in clinic. We also will estimate the incremental cost per woman screened of offering at-home HPV self-collection kits with scheduling assistance as compared to offering scheduling assistance alone. DISCUSSION: If mailed self-collection of samples for HPV testing is an effective strategy for increasing cervical cancer screening among women overdue for screening, this method has the potential to reduce cervical cancer incidence and mortality in medically underserved women at higher risk of developing cervical cancer. TRIAL REGISTRATION: ClinicalTrials.gov NCT02651883, Registered on 11 January 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Spees LP, Des Marais AC, Wheeler SB, et al. Impact of human papillomavirus (HPV) self-collection on subsequent cervical cancer screening completion among under-screened US women: MyBodyMyTest-3 protocol for a randomized controlled trial. Trials. 2019. PMID: 31881928. doi:10.1186/s13063-019-3959-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。